Evidence map›Paper›PMID 37761360›Full record

ArticleDiagnostics (Basel, Switzerland)2023

The Genomic Landscape of Colorectal Cancer in the Saudi Arabian Population Using a Comprehensive Genomic Panel.

Ebtehal Alsolme, Saleh Alqahtani, Musa Fageeh, Duna Barakeh, Nitesh K Sharma, Serghei Mangul, Heather A Robinson, Amany Fathaddin, Charlotte A E Hauser, Malak Abedalthagafi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Cancer Genetics in the Arab World.Technology in cancer research & treatment
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 3 countries.

Ebtehal AlsolmeGenomic Research Department, King Fahad Medical City, Riyadh 12231, Saudi Arabia.
Saleh AlqahtaniRoyal Clinic and Hepatology Department, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia.
Musa FageehPathology Department, King Saud Medical City, Riyadh 12746, Saudi Arabia.
Duna BarakehGenomic Research Department, King Fahad Medical City, Riyadh 12231, Saudi Arabia.ORCID 0000-0001-6395-7916
Nitesh K SharmaThe Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA 90007, USA.
Serghei MangulThe Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA 90007, USA.
Heather A RobinsonHealth eResearch, University of Manchester, Manchester M13 9PL, UK.
Amany FathaddinDepartment of Pathology, Collage of Medicine, King Saud University, Riyadh 11362, Saudi Arabia.
Charlotte A E HauserLaboratory for Nanomedicine, Biological & Environmental Science & Engineering (BESE) Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia.
Malak AbedalthagafiDepartment of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, GA 30307, USA.
King Fahd Medical City · SAUniversity of Southern California · USEmory University · USKing Abdullah University of Science and Technology · SAKing Faisal Specialist Hospital & Research Centre · SAKing Saud Medical City · SAKing Saud University · SAUniversity of Manchester · GB

Funding

Developing robust and scalable genomics tools and databases to analyze immune receptor repertoires across diverse populationsR01AI173172 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ALACHKAR, HOUDA · 2023 to 2025
$2.5M
NIAID NIH HHS R01 AI173172
6 · The paper itself

Abstract

purposeNext-generation sequencing (NGS) technology detects specific mutations that can provide treatment opportunities for colorectal cancer (CRC) patients. PATIENTS AND

methodsWe analyzed the mutation frequencies of common actionable genes and their association with clinicopathological characteristics and oncologic outcomes using targeted NGS in 107 Saudi Arabian patients without a family history of CRC.

resultsApproximately 98% of patients had genetic alterations. Frequent mutations were observed in

conclusionsThese results may help optimize personalized therapy when drugs specific to a patient's mutation profile have already been developed.

Indexed as

BRCA2colorectal cancerKRASNGSPIK3CASaudi genomeSaudi populationsomatic mutations

Identifiers

PMID37761360
PMCPMC10527739
OpenAlexW4386849413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.